Where I see patients (3)
Clinical trials
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Glioma...
Events occurring on or after treatment on Day 1 will be classified using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Adverse events leading to treatment discontinuation will be listed.
Recruiting
More about this study
ONC206 for Treatment of Newly Diagnosed, or Recurrent Diffuse Midline Gliomas, and Other Recurr...
A DLT is defined as a treatment-related adverse event (AE) or abnormal laboratory value that occurs in the first cycle of treatment (Cycle 1 for Arm A and D; Cycle 0 for Arm B and C), meets criteria for DLT as outlined below and i...
Recruiting
More about this study
Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients With Recurren...
We will employ the Bayesian optimal interval (BOIN) design to find the MTD for both continuous and intermittent dosing schedules. The BOIN design is implemented in a simple way similar to the traditional 3+3 design, but is more fl...
Recruiting
More about this study
Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or...
The safety of the modified measles virus will be assessed by monitoring for adverse events. Subjects will be monitored for adverse events via scheduled laboratory assessments, vital sign measurements, and physical examinations. Th...
Recruiting
More about this studyContact me
Staff superheroes
It’s a bird. It’s a plane. It’s a window washer! Dressed as a superhero to clean and brighten your day.
